tiprankstipranks
Viracta Therapeutics downgraded to Neutral from Buy at Rodman & Renshaw
PremiumThe FlyViracta Therapeutics downgraded to Neutral from Buy at Rodman & Renshaw
6M ago
Viracta Therapeutics Explores Strategic Options After NAVAL-1 Closure
Premium
Company Announcements
Viracta Therapeutics Explores Strategic Options After NAVAL-1 Closure
6M ago
Viracta Therapeutics announces exploration of strategic alternatives
Premium
The Fly
Viracta Therapeutics announces exploration of strategic alternatives
6M ago
Viracta Therapeutics Restructures to Focus on Nana-val Program
PremiumCompany AnnouncementsViracta Therapeutics Restructures to Focus on Nana-val Program
8M ago
VIRX Upcoming Earnings Report: What to Expect?
Premium
Pre-Earnings
VIRX Upcoming Earnings Report: What to Expect?
8M ago
Viracta Therapeutics downgraded to Market Perform from Outperform at Leerink
Premium
The Fly
Viracta Therapeutics downgraded to Market Perform from Outperform at Leerink
11M ago
VIRX Upcoming Earnings Report: What to Expect?
PremiumPre-EarningsVIRX Upcoming Earnings Report: What to Expect?
11M ago
Xoma receives $8.1M milestone related to Day One’s sale of PRV
Premium
The Fly
Xoma receives $8.1M milestone related to Day One’s sale of PRV
1y ago
Day One Biopharmaceuticals announces sale of Priority Review Voucher for $108M
Premium
The Fly
Day One Biopharmaceuticals announces sale of Priority Review Voucher for $108M
1y ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100